Publications by authors named "Kari Fonseca"

Claim this Profile
S
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy.
Ruolun Qiu, Kari Fonseca, Arthur Bergman, Jian Lin, David Tess

Clin Transl Sci· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industry Perspective on Therapeutic Peptide Drug-Drug Interaction Assessments During Drug Development: A European Federation of Pharmaceutical Industries and Associations White Paper.
Carolina Säll, Upendra Argikar, Kari Fonseca, Constanze Hilgendorf, Filipe Lopes

Clin Pharmacol Ther· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss.
Michelle R Garnsey, Aaron C Smith, Jana Polivkova, Autumn L Arons, Guoyun Bai, Kari R Fonseca

J Med Chem· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a Ketohexokinase Inhibitor (PF-06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug.
David A Tess, Emi Kimoto, Amanda King-Ahmad, Manoli Vourvahis, A David Rodrigues, Kari R Fonseca

Clin Pharmacol Ther· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
.
.
Yan Weng, Kari R Fonseca, Yi-An Bi, Sumathy Mathialagan, Keith Riccardi

Drug Metab Dispos· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target occupancy study and whole-body dosimetry with a MAGL PET ligand [C]PF-06809247 in non-human primates.
Ryosuke Arakawa, Akihiro Takano, Sangram Nag, Zhisheng Jia, Nahid Amini, Kari R Fonseca

EJNMMI Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effects of a Novel Non-catechol Dopamine Partial Agonist on Working Memory in the Aged Rhesus Monkey.
Tara L Moore, Damon A Young, Ronald J Killiany, Kari R Fonseca, Dmitri Volfson

Front Aging Neurosci· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects.
Damon Young, Michael Popiolek, Patrick Trapa, Kari R Fonseca, Julie Brevard

ACS Chem Neurosci· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition.
Cheng Chang, Kari R Fonseca, Cheryl Li, Weldon Horner, Laura E Zawadzke

Mol Pharmacol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of Neuroinflammation.
Laura A McAllister, Christopher R Butler, Scot Mente, Steven V O'Neil, Kari R Fonseca

J Med Chem· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azetidine and Piperidine Carbamates as Efficient, Covalent Inhibitors of Monoacylglycerol Lipase.
Christopher R Butler, Elizabeth M Beck, Anthony Harris, Zhen Huang, Laura A McAllister, Kari Fonseca

J Med Chem· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral Administration of a Long-Acting Peptide Oxytocin Receptor Agonist Inhibits Fear-Induced Freezing.
Meera E Modi, Mark J Majchrzak, Kari R Fonseca, Angela Doran, Sarah Osgood

J Pharmacol Exp Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network.
Simone Sciabola, Gilles H Goetz, Guoyun Bai, Bruce N Rogers, David L Gray, Kari R Fonseca

Bioorg Med Chem· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of brain kynurenic acid improves cognitive function.
Rouba Kozak, Brian M Campbell, Christine A Strick, Weldon Horner, William E Hoffmann, Kari Fonseca

J Neurosci· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.
Lei Zhang, Gayatri Balan, Gabriela Barreiro, Brian P Boscoe, Lois K Chenard, Kari R Fonseca

J Med Chem· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions.
Jamison B Tuttle, Marie Anderson, Bruce M Bechle, Brian M Campbell, Cheng Chang, Kari R Fonseca

ACS Med Chem Lett· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.
Patrick R Verhoest, Kari R Fonseca, Xinjun Hou, Caroline Proulx-Lafrance, Michael Corman

J Med Chem· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
Michelle M Claffey, Christopher J Helal, Patrick R Verhoest, Zhijun Kang, Kristina S Fors, Kari R Fonseca

J Med Chem· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
Robin J Kleiman, Douglas S Chapin, Curt Christoffersen, Jody Freeman, Kari R Fonseca

J Pharmacol Exp Ther· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism.
Jill L Silverman, Daniel G Smith, Stacey J Sukoff Rizzo, Michael N Karras, Sarah M Turner, Kari Fonseca

Sci Transl Med· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia.
Amy B Dounay, Marie Anderson, Bruce M Bechle, Brian M Campbell, Michelle M Claffey, Kari R Fonseca

ACS Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.
Christopher J Helal, Zhijun Kang, Xinjun Hou, Jayvardhan Pandit, Thomas A Chappie, Kari R Fonseca

J Med Chem· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.
Patrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, Lois Chenard, Christopher J Helal, Kari R Fonseca

J Med Chem· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Patrick R Verhoest, Douglas S Chapin, Michael Corman, Kari Fonseca, John F Harms

J Med Chem· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis